MX2020000611A - Composiciones y metodos para tratar trastornos relacionados con el estres. - Google Patents

Composiciones y metodos para tratar trastornos relacionados con el estres.

Info

Publication number
MX2020000611A
MX2020000611A MX2020000611A MX2020000611A MX2020000611A MX 2020000611 A MX2020000611 A MX 2020000611A MX 2020000611 A MX2020000611 A MX 2020000611A MX 2020000611 A MX2020000611 A MX 2020000611A MX 2020000611 A MX2020000611 A MX 2020000611A
Authority
MX
Mexico
Prior art keywords
compositions
related disorders
treating stress
stress
treating
Prior art date
Application number
MX2020000611A
Other languages
English (en)
Inventor
Steven Hoffman
John Rothman
Original Assignee
Hoffman Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/653,837 external-priority patent/US10426836B2/en
Application filed by Hoffman Tech Llc filed Critical Hoffman Tech Llc
Publication of MX2020000611A publication Critical patent/MX2020000611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las presentes invenciones se refieren en general a composiciones, equipos y métodos para el tratamiento de trastornos relacionados con el estrés, que incluyen pero no se limitan a trastorno de estrés postraumático.
MX2020000611A 2017-07-19 2018-07-19 Composiciones y metodos para tratar trastornos relacionados con el estres. MX2020000611A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/653,837 US10426836B2 (en) 2017-07-19 2017-07-19 Compositions and methods for treating stress-related disorders
US201862628687P 2018-02-09 2018-02-09
PCT/US2018/042874 WO2019018633A1 (en) 2017-07-19 2018-07-19 COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS

Publications (1)

Publication Number Publication Date
MX2020000611A true MX2020000611A (es) 2020-09-10

Family

ID=63104146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000611A MX2020000611A (es) 2017-07-19 2018-07-19 Composiciones y metodos para tratar trastornos relacionados con el estres.

Country Status (11)

Country Link
EP (1) EP3655036A1 (es)
JP (1) JP7170722B2 (es)
KR (1) KR20200038481A (es)
CN (1) CN111032089A (es)
AU (1) AU2018302248A1 (es)
BR (1) BR112020001074A2 (es)
CA (1) CA3069703A1 (es)
IL (1) IL272061A (es)
MX (1) MX2020000611A (es)
PH (1) PH12020550023A1 (es)
WO (1) WO2019018633A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2719575C1 (ru) * 2019-02-01 2020-04-21 Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" Фармацевтическая композиция на основе альфа-метил-п-тирозина и способ ранней диагностики болезни Паркинсона
EA202192084A1 (ru) * 2019-02-01 2021-10-20 ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи. Композиции и способы для лечения связанных с тревожностью нарушений
AU2020257406A1 (en) * 2019-04-19 2021-12-16 Hoffman Technologies Llc Sustained release formulations
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20220002151A (ko) 2020-06-30 2022-01-06 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물
WO2022192397A1 (en) * 2021-03-09 2022-09-15 Hoffman Technologies Llc Chewable formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160835A (en) 1976-11-19 1979-07-10 Merck & Co., Inc. Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
JPS58105916A (ja) * 1981-12-16 1983-06-24 Nippon Chibagaigii Kk 癌治療剤
CN1042707A (zh) * 1988-11-18 1990-06-06 宋玉富 牛胆汁提取胆红素的生产工艺
AU3783799A (en) * 1998-05-05 1999-11-23 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
BR112012010866A2 (pt) * 2009-11-09 2016-11-29 Genepod Therapeutics Ab "nova construção de vetor viral para síntese específica otimizada contínua de dopa por neurônios in vivo".
CN101797251A (zh) * 2010-01-21 2010-08-11 复旦大学 人类病原体艰难梭菌中乙酰辅酶a合成酶的抑制剂
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9949923B2 (en) * 2011-03-15 2018-04-24 Optinose As Nasal delivery
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
GB201216800D0 (en) * 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
WO2014078724A1 (en) * 2012-11-16 2014-05-22 Finzi Eric Treatment of post-traumatic stress disorder using botulinum toxin a
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
CN106025267B (zh) * 2016-06-24 2018-06-05 合肥国轩高科动力能源有限公司 一种核壳结构的微米级镍锰酸锂材料改性方法

Also Published As

Publication number Publication date
JP7170722B2 (ja) 2022-11-14
IL272061A (en) 2020-03-31
CN111032089A (zh) 2020-04-17
BR112020001074A2 (pt) 2020-07-14
PH12020550023A1 (en) 2021-02-08
KR20200038481A (ko) 2020-04-13
WO2019018633A1 (en) 2019-01-24
EP3655036A1 (en) 2020-05-27
AU2018302248A1 (en) 2020-01-30
CA3069703A1 (en) 2019-01-24
JP2020528929A (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
AU2016263598A8 (en) Methods and kits for treating depression
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2022015456A (es) Composiciones de maca y metodos de uso.
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12019500479A1 (en) Compositions for treating dementia
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
MX2019010060A (es) Composiciones y metodo para tratar cancer.